Brilinta reduces CV events in patients without prior heart attack, stroke

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor met the primary endpoint of reducing major adverse cardiovascular events (MACE) in the Phase III THEMIS trial in patients with coronary artery disease and Type II diabetes with no prior myocardial infarction (MI) or stroke.

In 19,271 patients, Brilinta plus aspirin significantly reduced a composite of cardiovascular death, MI and stroke vs. aspirin alone. Full data from the double-blind, international trial are expected this year...